Discontinued operations generated a loss for the period of € (6) m on an IFRS basis, but a profit of € 133 m on an underlying basis. The € 138 m adjustment made to the IFRS profit consists of:

  • € 129 m for Indupa, including adjustments to fair value and €54 m for the recycling of negative currency translation adjustments at the closing of the divestment in December;
  • € 26 m for costs related to the divestment of Acetow and Vinythai, including PPA depreciation;
  • € (17) m related to gains on the divested pharma activities, as underlying results exclude post-closing elements.